PapersFlow Research Brief

Health Sciences · Medicine

Dermatological and COVID-19 studies
Research Guide

What is Dermatological and COVID-19 studies?

Dermatological and COVID-19 studies is a cluster of research examining the dermatologic manifestations of COVID-19, such as cutaneous signs, chilblain-like lesions, pernio, oral manifestations, erythema nodosum, vesicular rash, and associated histopathological findings.

This field includes 23,934 works focused on skin lesions linked to COVID-19 infection. Studies cover histopathological analyses and reviews of various cutaneous presentations. Growth rate over the past 5 years is not available in the data.

Topic Hierarchy

100%
graph TD D["Health Sciences"] F["Medicine"] S["Dermatology"] T["Dermatological and COVID-19 studies"] D --> F F --> S S --> T style T fill:#DC5238,stroke:#c4452e,stroke-width:2px
Scroll to zoom • Drag to pan
23.9K
Papers
N/A
5yr Growth
148.9K
Total Citations

Research Sub-Topics

Why It Matters

Dermatological and COVID-19 studies identify skin findings that aid in early detection and severity assessment of COVID-19 cases. For instance, "High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa" by Xu et al. (2020) showed high ACE2 receptor presence on oral epithelial cells, indicating oral mucosa as a potential entry site for SARS-CoV-2 and explaining observed oral manifestations. "Multiorgan and Renal Tropism of SARS-CoV-2" by Puelles et al. (2020) demonstrated SARS-CoV-2 tropism beyond the respiratory tract to organs including skin-relevant tissues in autopsy series, supporting dermatologic signs as indicators of systemic involvement. "Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study" by Tan et al. (2020) linked lymphopenia to disease severity, a finding relevant to inflammatory skin responses in COVID-19 patients.

Reading Guide

Where to Start

"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa" by Xu et al. (2020), as it directly addresses a key dermatologic manifestation with clear evidence of ACE2 expression on oral mucosa relevant to COVID-19 skin studies.

Key Papers Explained

"APACHE II: a severity of disease classification system" by Knaus et al. (1985) provides a foundational severity scoring method applicable to COVID-19 patients with skin lesions. "High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa" by Xu et al. (2020) builds on this by linking ACE2 to oral manifestations, a dermatologic entry point. "Multiorgan and Renal Tropism of SARS-CoV-2" by Puelles et al. (2020) extends to systemic tropism including skin-relevant tissues, while "Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study" by Tan et al. (2020) and "Hematological findings and complications of COVID‐19" by Terpos et al. (2020) connect blood markers to severity in dermatologic contexts.

Paper Timeline

100%
graph LR P0["Measurement of Cutaneous Inflamm...
1982 · 3.6K cites"] P1["APACHE II: a severity of disease...
1985 · 6.0K cites"] P2["APACHE II-A Severity of Disease ...
1986 · 13.4K cites"] P3["Report of the Committee on Infec...
1989 · 1.9K cites"] P4["High expression of ACE2 receptor...
2020 · 2.9K cites"] P5["Coagulopathy and Antiphospholipi...
2020 · 2.2K cites"] P6["Multiorgan and Renal Tropism of ...
2020 · 1.9K cites"] P0 --> P1 P1 --> P2 P2 --> P3 P3 --> P4 P4 --> P5 P5 --> P6 style P2 fill:#DC5238,stroke:#c4452e,stroke-width:2px
Scroll to zoom • Drag to pan

Most-cited paper highlighted in red. Papers ordered chronologically.

Advanced Directions

Research emphasizes histopathological studies of chilblain-like lesions and vesicular rashes, with no recent preprints or news available. Focus remains on established papers like Xu et al. (2020) and Puelles et al. (2020) for multiorgan implications.

Papers at a Glance

# Paper Year Venue Citations Open Access
1 APACHE II-A Severity of Disease Classification System 1986 Critical Care Medicine 13.4K
2 APACHE II: a severity of disease classification system. 1985 PubMed 6.0K
3 Measurement of Cutaneous Inflammation: Estimation of Neutrophi... 1982 Journal of Investigati... 3.6K
4 High expression of ACE2 receptor of 2019-nCoV on the epithelia... 2020 International Journal ... 2.9K
5 Coagulopathy and Antiphospholipid Antibodies in Patients with ... 2020 New England Journal of... 2.2K
6 Report of the Committee on Infectious Diseases 1989 Archives of Dermatology 1.9K
7 Multiorgan and Renal Tropism of SARS-CoV-2 2020 New England Journal of... 1.9K
8 Hematological findings and complications of <scp>COVID</scp>‐19 2020 American Journal of He... 1.7K
9 Acute pancreatitis: value of CT in establishing prognosis. 1990 Radiology 1.7K
10 Lymphopenia predicts disease severity of COVID-19: a descripti... 2020 Signal Transduction an... 1.6K

Frequently Asked Questions

What are common dermatologic manifestations of COVID-19?

Common manifestations include cutaneous signs, chilblain-like lesions, pernio, oral manifestations, erythema nodosum, and vesicular rash. These are documented across 23,934 works in the field. Histopathological studies provide further characterization of these skin lesions.

How does ACE2 receptor expression relate to COVID-19 oral manifestations?

"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa" by Xu et al. (2020) found high ACE2 expression on oral epithelial cells. This supports oral mucosa as a SARS-CoV-2 entry point. It explains observed oral manifestations in COVID-19 patients.

What role does lymphopenia play in COVID-19 severity?

"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study" by Tan et al. (2020) established lymphopenia as a predictor of disease severity. This finding has prognostic value in COVID-19 cases with dermatologic signs. It correlates with systemic inflammation affecting skin.

What is the organ tropism of SARS-CoV-2?

"Multiorgan and Renal Tropism of SARS-CoV-2" by Puelles et al. (2020) identified SARS-CoV-2 presence in kidneys, heart, liver, brain, and beyond the respiratory tract in autopsies. This multiorgan involvement includes tissues relevant to dermatologic manifestations. It underscores skin lesions as systemic indicators.

How is disease severity measured in critical COVID-19 contexts?

"APACHE II: a severity of disease classification system" by Knaus et al. (1985) introduced APACHE II, using 12 physiologic measurements, age, and health status for severity scoring. An increased score predicts higher hospital mortality. This system applies to COVID-19 patients exhibiting dermatologic signs.

What hematological changes occur in COVID-19?

"Hematological findings and complications of COVID‐19" by Terpos et al. (2020) reported lymphopenia as a cardinal finding with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio also show prognostic value. These changes relate to inflammatory dermatologic responses.

Open Research Questions

  • ? How do chilblain-like lesions and pernio specifically correlate with COVID-19 histopathological changes?
  • ? What is the precise mechanism of vesicular rash and erythema nodosum in SARS-CoV-2 infection?
  • ? Does high oral ACE2 expression predict severity of cutaneous manifestations across patient cohorts?
  • ? How does multiorgan tropism of SARS-CoV-2 influence the progression of skin lesions?
  • ? Can lymphopenia and neutrophil/lymphocyte ratios serve as biomarkers for dermatologic COVID-19 outcomes?

Research Dermatological and COVID-19 studies with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Dermatological and COVID-19 studies with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers